Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

REGO-EWING: Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing Sarcoma

Ewing Sarcoma

Status: Open | QLD , VIC , WA

The effectiveness of new drugs in Ewing Sarcoma has been disappointing over prior decades and no new drugs have been successfully introduced into first-line treatment to date.

Early clinical data suggests that strategies using multi-target tyrosine kinase (TKI) inhibitors with anti-angiogenic activities are among the most effective and may be beneficial in the treatment of patients with Ewing Sarcoma. Regorafenib has shown promising activity in relapsed Ewing Sarcoma.

Nevertheless, Regorafenib has never been combined with the, now standard, intensive VDC/IE chemotherapy regimen.

REGO-EWING was designed to test the feasibility of regorafenib with conventional Ewing Sarcoma chemotherapy. It consists of a phase Ib that will only recruit patients with multi-metastatic (other than lungs/ pleura only) Ewing Sarcoma, that present the highest unmet medical need for prognosis.

Disease Stage – Newly Diagnosed

Patient Age Range – 2 – 50 years of age at time of diagnosis

Trial sponsors

  • National – ANZCHOG
  • International – Gustave Roussy

ANZCHOG acknowledges the valuable support of REGO-EWING by Canteen Australia’s Australian Young Cancer Patient Clinical Trials Initiative, which is supported by the Commonwealth Department of Health via the Medical Research Future Fund, The Kids' Cancer Project and the Cooper Rice-Brading Foundation, the Australian Government's Medical Research Future Fund (through the 2021 Rare Cancers, Rare Diseases and Unmet Need MRF2015073) and our clinical collaborators Australia and New Zealand Sarcoma Association (ANZSA) supported by their philanthropic partner the GPA Andrew Ursini Charitable Fund.